{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:19:37Z","timestamp":1783174777742,"version":"3.54.6"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274008"],"award-info":[{"award-number":["82274008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173889"],"award-info":[{"award-number":["82173889"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073930"],"award-info":[{"award-number":["82073930"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004605","name":"Zhengzhou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.dmd.2026.100309","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:26:51Z","timestamp":1777480011000},"page":"100309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical discovery of anti-CYP2E1 autoantibodies and preclinical efficacy of a CYP2E1 inhibitor in rheumatoid arthritis"],"prefix":"10.1016","volume":"54","author":[{"given":"Liyuan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8533-344X","authenticated-orcid":false,"given":"Hailing","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dmd.2026.100309_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis \u2014 common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dmd.2026.100309_bib2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.mayocp.2019.01.002","article-title":"Trends in prevalence of functional disability in rheumatoid arthritis compared with the general population","volume":"94","author":"Myasoedova","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"10416","key":"10.1016\/j.dmd.2026.100309_bib3","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100309_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S2215-0366(18)30255-4","article-title":"Rheumatoid arthritis and depression: an inflammatory perspective","volume":"6","author":"Nerurkar","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.dmd.2026.100309_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","article-title":"Signaling pathways in rheumatoid arthritis: implications for targeted therapy","volume":"8","author":"Ding","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"43","key":"10.1016\/j.dmd.2026.100309_bib6","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2213373119","article-title":"Photoacoustic image-guided biomimetic nanoparticles targeting rheumatoid arthritis","volume":"119","author":"Chen","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.dmd.2026.100309_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/art.43026","article-title":"JAK inhibitors versus biologic disease-modifying antirheumatic drugs: which is more effective for rheumatoid arthritis pain?","volume":"77","author":"Weiland","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100309_bib8","first-page":"1247","article-title":"Novel insights into the management of rheumatoid arthritis: one year in review 2022","volume":"40","author":"Garaffoni","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100309_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nrd.2016.21","article-title":"Rheumatoid arthritis: current and future trends","volume":"15","author":"Chaudhari","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"2-3","key":"10.1016\/j.dmd.2026.100309_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","article-title":"Immunogenicity of anti-TNF-\u03b1 agents in autoimmune diseases","volume":"38","author":"Emi Aikawa","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"10.1016\/j.dmd.2026.100309_bib11","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.dmd.2026.100309_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002236","article-title":"Waiting for JAK inhibitor safety data","volume":"8","author":"Kragstrup","year":"2022","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.dmd.2026.100309_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100309_bib14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/annrheumdis-2020-217485","article-title":"Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial","volume":"79","author":"van Mulligen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.dmd.2026.100309_bib15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/ard-2023-224692","article-title":"Annals of the Rheumatic Diseases collection on autoantibodies in the rheumatic diseases: new insights into pathogenesis and the development of novel biomarkers","volume":"82","author":"Pisetsky","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.dmd.2026.100309_bib16","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/art.43168","article-title":"Anti-peptidylarginine deiminase 4 autoantibodies derived from patients with rheumatoid arthritis exert pathogenic effects by activating monocytes and exacerbating inflammatory arthritis","volume":"77","author":"Won","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100309_bib17","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/ijms21041382","article-title":"Autoantibody biomarkers in rheumatic diseases","volume":"21","author":"Kang","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100309_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/ard-2022-223417","article-title":"Divergent and dominant anti-inflammatory effects of patient-derived anticitrullinated protein antibodies (ACPA) in arthritis development","volume":"82","author":"Raposo","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.dmd.2026.100309_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/03602532.2019.1632889","article-title":"A comprehensive review of cytochrome P450 2E1 for xenobiotic metabolism","volume":"51","author":"Chen","year":"2019","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmd.2026.100309_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103107","article-title":"ERR\u03b3-inducible FGF23 promotes alcoholic liver injury through enhancing CYP2E1 mediated hepatic oxidative stress","volume":"71","author":"Jung","year":"2024","journal-title":"Redox Biol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100309_bib21","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1097\/HEP.0000000000001282","article-title":"Repression of the ERR\u03b3-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injury","volume":"82","author":"Wang","year":"2025","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.dmd.2026.100309_bib22","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/hep.22222","article-title":"Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice","volume":"47","author":"Lu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.dmd.2026.100309_bib23","first-page":"303","article-title":"Translational implications of the alcohol-metabolizing enzymes, including cytochrome P450-2E1, in alcoholic and nonalcoholic liver disease","volume":"vol 74","author":"Song","year":"201574"},{"issue":"10","key":"10.1016\/j.dmd.2026.100309_bib24","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/hep4.1115","article-title":"The role of human cytochrome P450 2E1 in liver inflammation and fibrosis","volume":"1","author":"Xu","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dmd.2026.100309_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115160","article-title":"Cytochrome P450 2E1 gene knockout or inhibition prevents obesity induced by high-fat diet via regulating energy expenditure","volume":"202","author":"Zhang","year":"2022","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100309_bib26","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/hep.30652","article-title":"Fructose promotes leaky gut, endotoxemia, and liver fibrosis through ethanol-inducible cytochrome P450-2E1-Mediated oxidative and nitrative stress","volume":"73","author":"Cho","year":"2021","journal-title":"Hepatology"},{"issue":"23","key":"10.1016\/j.dmd.2026.100309_bib27","article-title":"Identification of cytochrome P450 2E1 as a novel target in glioma and development of its inhibitor as an anti-tumor agent","volume":"10","author":"Hu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"35","key":"10.1016\/j.dmd.2026.100309_bib28","article-title":"A novel cytochrome P450 2E1 inhibitor Q11 is effective on lung cancer via regulation of the inflammatory microenvironment","volume":"10","author":"Jia","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.dmd.2026.100309_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139189","article-title":"Cytochrome P450 2E1 inhibitor Q11 is effective on hepatocellular carcinoma by promoting peritumor neutrophil chemotaxis","volume":"293","author":"Gu","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.dmd.2026.100309_bib30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.redox.2014.11.004","article-title":"CYP2E1 autoantibodies in liver diseases","volume":"3","author":"Sutti","year":"2014","journal-title":"Redox Biol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100309_bib31","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1007\/s00204-022-03326-x","article-title":"Increased serum anti-CYP2E1 IgG autoantibody levels may be involved in the pathogenesis of occupational trichloroethylene hypersensitivity syndrome: a case-control study","volume":"96","author":"Nakajima","year":"2022","journal-title":"Arch Toxicol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100309_bib32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jhep.2006.11.009","article-title":"Detection of auto-antibodies against cytochrome P4502E1 (CYP2E1) in chronic hepatitis C","volume":"46","author":"Vidali","year":"2007","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100309_bib33","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/art.40408","article-title":"Hypomethylation of CYP2E1 and DUSP22 promoters associated with disease activity and erosive disease among rheumatoid arthritis patients","volume":"70","author":"Mok","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.dmd.2026.100309_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116501","article-title":"Discovery of CYP2E1 as a novel target in rheumatoid arthritis and validation by a new specific CYP2E1 inhibitor","volume":"229","author":"Han","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmd.2026.100309_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117666","article-title":"Discovery of a CYP2E1 inhibitor and its therapeutic potential in severe acute pancreatitis","volume":"292","author":"Qiu","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.dmd.2026.100309_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.109492","article-title":"4-methyl-5-acetylthiazole (Q11), a novel CYP2E1 inhibitor, has a protective effect on the hepatotoxicity induced by acetaminophen","volume":"170","author":"Yu","year":"2026","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.dmd.2026.100309_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115638","article-title":"The CYP2E1 inhibitor Q11 ameliorates LPS-induced sepsis in mice by suppressing oxidative stress and NLRP3 activation","volume":"214","author":"Gao","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100309_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00262-024-03912-1","article-title":"Q11, a CYP2E1 inhibitor, exerts anti-hepatocellular carcinoma effect by inhibiting M2 macrophage polarization","volume":"74","author":"Zhang","year":"2024","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1016\/j.dmd.2026.100309_bib39","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1248\/bpb.28.1221","article-title":"Inhibition of human cytochrome P450 2E1 by halogenated anilines, phenols, and thiophenols","volume":"28","author":"Ohashi","year":"2005","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"10.1016\/j.dmd.2026.100309_bib40","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/096032719701600505","article-title":"Low-dose diethyldithiocarbamate attenuates the hepatotoxicity of 1,3-dichloro-2-propanol and selectively inhibits CYP2E1 activity in the rat","volume":"16","author":"Stott","year":"1997","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.dmd.2026.100309_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.toxlet.2018.04.023","article-title":"In vitro evaluation of structural analogs of diallyl sulfide as novel CYP2E1 inhibitors for their protective effect against xenobiotic-induced toxicity and HIV replication","volume":"292","author":"Rahman","year":"2018","journal-title":"Toxicol Lett"},{"issue":"2","key":"10.1016\/j.dmd.2026.100309_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrrheum.2016.200","article-title":"Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis","volume":"13","author":"Catrina","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100309_bib43","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.dmd.2026.100309_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.655477","article-title":"A tale of two immune cells in rheumatoid arthritis: the crosstalk between macrophages and T cells in the synovium","volume":"12","author":"Tu","year":"2021","journal-title":"Front Immunol"},{"issue":"7760","key":"10.1016\/j.dmd.2026.100309_bib45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"issue":"43","key":"10.1016\/j.dmd.2026.100309_bib46","doi-asserted-by":"crossref","first-page":"26895","DOI":"10.1073\/pnas.2011667117","article-title":"TLR4 signaling and macrophage inflammatory responses are dampened by GIV\/Girdin","volume":"117","author":"Swanson","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.dmd.2026.100309_bib47","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/ard-2022-222708","article-title":"PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes","volume":"82","author":"Tu","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.dmd.2026.100309_bib48","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41590-023-01527-9","article-title":"Drivers of heterogeneity in synovial fibroblasts in rheumatoid arthritis","volume":"24","author":"Smith","year":"2023","journal-title":"Nat Immunol"},{"issue":"40","key":"10.1016\/j.dmd.2026.100309_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq0959","article-title":"NIR-photocatalytic regulation of arthritic synovial microenvironment","volume":"8","author":"Zhao","year":"2022","journal-title":"Sci Adv"},{"issue":"44","key":"10.1016\/j.dmd.2026.100309_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb0606","article-title":"Induced, but not natural, regulatory T cells retain phenotype and function following exposure to inflamed synovial fibroblasts","volume":"6","author":"Yang","year":"2020","journal-title":"Sci Adv"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:53:34Z","timestamp":1783173214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0090955626000784"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100309","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical discovery of anti-CYP2E1 autoantibodies and preclinical efficacy of a CYP2E1 inhibitor in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100309"}}